Stock Library / BBIO

BBIO Healthcare Latest YouTube: Q2 2026 Published 2026-08-13

BridgeBio Pharma, Inc.

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Spotify Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

BridgeBio (BBIO) Q2 2026: Attruby Up 211%, And The $934M Preferred

Published 2026-08-13

Open YouTube Open Spotify Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q2 2026

2026-08-13

Podcast available

Yes

Current price

$80.13

+0.55 (+0.69%)

Trailing / Forward P/E

—

Forward: 216.46x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

120.4%

Earnings: —

Margins

-43.9% op

Gross: 94.4% · Net: -97.0%

Balance sheet

1.23x current

Debt / Equity: —

52-week range / Beta

$46.81 - $93.42

Beta: 0.98

Analyst target

$108.43

Upside: 35.3%

Cash / shareholder return

-2.04% FCF yield

Dividend yield: —

Company context

Industry: Biotechnology

Country: United States

Employees: —

Price to book: -6.88x

Return on equity: —

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Price chart

Market context for BBIO

Competitive view

BBIO vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

BridgeBio Pharma, Inc. latest YouTube video thumbnail

BridgeBio Pharma, Inc.

BBIO

YouTube Spotify Podbean

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Intuitive Surgical latest YouTube video thumbnail

Intuitive Surgical

ISRG

YouTube Spotify Podbean Apple

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Johnson & Johnson latest YouTube video thumbnail

Johnson & Johnson

JNJ

YouTube Podbean Apple

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

BBIO

$15.66B

BridgeBio Pharma, Inc.

ISRG

$142.77B

Intuitive Surgical

JNJ

$629.14B

Johnson & Johnson

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

BBIO

—

BridgeBio Pharma, Inc.

ISRG

45.8x

Intuitive Surgical

JNJ

30.3x

Johnson & Johnson

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

BBIO

216.5x

BridgeBio Pharma, Inc.

ISRG

33.0x

Intuitive Surgical

JNJ

21.2x

Johnson & Johnson

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

BBIO

120.4%

BridgeBio Pharma, Inc.

ISRG

18.5%

Intuitive Surgical

JNJ

6.6%

Johnson & Johnson

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

BBIO

—

BridgeBio Pharma, Inc.

ISRG

26.5%

Intuitive Surgical

JNJ

-0.9%

Johnson & Johnson

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

BBIO

-43.9%

BridgeBio Pharma, Inc.

ISRG

33.6%

Intuitive Surgical

JNJ

29.2%

Johnson & Johnson

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

BBIO

94.4%

BridgeBio Pharma, Inc.

ISRG

66.7%

Intuitive Surgical

JNJ

68.1%

Johnson & Johnson

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

BBIO

-97.0%

BridgeBio Pharma, Inc.

ISRG

28.4%

Intuitive Surgical

JNJ

21.5%

Johnson & Johnson

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

BBIO

—

BridgeBio Pharma, Inc.

ISRG

17.4%

Intuitive Surgical

JNJ

25.7%

Johnson & Johnson

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

BBIO

-2.0%

BridgeBio Pharma, Inc.

ISRG

1.8%

Intuitive Surgical

JNJ

2.7%

Johnson & Johnson

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

BBIO

—

BridgeBio Pharma, Inc.

ISRG

—

Intuitive Surgical

JNJ

57.71x

Johnson & Johnson

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

BBIO

1.23x

BridgeBio Pharma, Inc.

ISRG

4.96x

Intuitive Surgical

JNJ

1.09x

Johnson & Johnson

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

BBIO

0.98

BridgeBio Pharma, Inc.

ISRG

1.46

Intuitive Surgical

JNJ

0.23

Johnson & Johnson

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

BBIO

—

BridgeBio Pharma, Inc.

ISRG

—

Intuitive Surgical

JNJ

2.0%

Johnson & Johnson

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

BBIO

35.3%

BridgeBio Pharma, Inc.

ISRG

20.0%

Intuitive Surgical

JNJ

4.4%

Johnson & Johnson

Related research

Non-quarter videos featuring BBIO

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-13

BBIO Stock: BridgeBio Q2 2026 Earnings - Attruby Up 211%, Still A $152M Loss

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for BBIO

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-08-13

Published youtube podcast complete

BridgeBio (BBIO) Q2 2026: Attruby Up 211%, And The $934M Preferred

Quarterly earnings-analysis entry for BridgeBio Pharma, Inc.. Use the links on the right to open the video or podcast episode.

YouTube Spotify Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music